Sale of pharmaceutical company for a seven-figure plus deferred consideration

We worked on the share sale of a pharmaceutical distributor on the sale of their entire issued share capital to a large multinational eye healthcare manufacturer looking to diversify its portfolio.

The sale involved negotiating and amending the terms of a share purchase agreement prepared by a team of US based lawyers.

It was complicated by the need to make a provision for an on-going consultancy arrangement between the sellers and purchaser. The deal also required the incorporation of deferred consideration provisions tied to the future success of products sold by the company or any of its affiliates. This meant the value of the deal was heavily tied to the subsequent sales and we addressed this within the transaction documents.

From the date of instruction to the completion date, the sale was completed in under a month.